Valuation: Astellas Pharma Inc.

Market Cap 4,025B 25.48B 22.65B 21.12B 19.25B 36.3B 2,455B 36.66B 254B 99.1B 1,252B 95.75B 93.67B P/E 2027 *
10.5x
P/E 2028 * 11.1x
Enterprise Value 3,966B 25.1B 22.32B 20.81B 18.97B 35.77B 2,419B 36.12B 250B 97.65B 1,234B 94.34B 92.3B EV / Sales 2027 *
1.69x
EV / Sales 2028 * 1.62x
Free-Float
98.92%
Yield 2027 *
3.57%
Yield 2028 * 3.7%
1 day+0.80%
1 week-2.33%
Current month-1.56%
1 month-5.26%
3 months+12.50%
6 months-11.21%
Current year+13.21%
1 week 12.5
Extreme 12.5
12.9
1 month 11.9
Extreme 11.9
13.2
Current year 11
Extreme 11
14.19
1 year 8.56
Extreme 8.56
14.19
3 years 7.53
Extreme 7.534
14.19
5 years 7.53
Extreme 7.534
15.62
10 years 7.53
Extreme 7.534
16.7
Manager TitleAgeSince
Chief Executive Officer 64 09/02/2023
Director of Finance/CFO 55 31/10/2023
Compliance Officer - 31/03/2025
Director TitleAgeSince
Chairman 66 09/02/2023
Director/Board Member 64 31/05/2019
Director/Board Member 59 31/05/2023
Change 5-day change 1-year change 3-year change Capi.($)
+0.80%-2.33% - - 26.3B
-0.61%-3.30%+38.46%+112.77% 1,025B
-1.02%-5.41%+37.61%+64.39% 623B
+1.11%-0.87%+7.55%+76.32% 459B
+0.34%-2.49%+60.10%+40.17% 355B
-0.95%-4.87%+22.46%+38.03% 336B
-1.46%-2.20%+11.84%+23.94% 270B
-1.35%-4.27%-4.55%+6.92% 247B
-1.04%-0.74%+35.02%+49.96% 220B
-1.87%-3.31%+30.22%+93.14% 183B
Average -0.22%-1.89%+26.52%+56.18% 413.14B
Weighted average by Cap. -0.11%-2.11%+29.72%+68.31%

Financials

2027 *2028 *
Net sales 2,347B 14.85B 13.21B 12.31B 11.22B 21.16B 1,431B 21.37B 148B 57.77B 730B 55.81B 54.61B 2,189B 13.86B 12.32B 11.49B 10.47B 19.75B 1,335B 19.94B 138B 53.9B 681B 52.07B 50.95B
Net income 367B 2.32B 2.06B 1.92B 1.75B 3.31B 224B 3.34B 23.15B 9.03B 114B 8.72B 8.54B 346B 2.19B 1.94B 1.81B 1.65B 3.12B 211B 3.15B 21.81B 8.51B 107B 8.22B 8.04B
Net Debt -59.18B -375M -333M -311M -283M -534M -36.09B -539M -3.74B -1.46B -18.41B -1.41B -1.38B -481B -3.04B -2.71B -2.52B -2.3B -4.34B -293B -4.38B -30.34B -11.83B -150B -11.43B -11.19B
Logo Astellas Pharma Inc.
Astellas Pharma Inc is a Japan-based company mainly engaged in the research, development, manufacture and sales of pharmaceutical products. The Company mainly operates Pharmaceutical Products business segment. The main products include XTANDI, BETANIS, MIRABETRIC, BETMIGA and new products ZOSPATA, EVERENZO and ENHOLTUMAB VEDOTIN, among others.
Employees
14,099
Date Price Change Volume
02/10/26 €12.50 0.00% 0
01/10/26 €12.50 -2.34% 200
30/09/26 €12.80 +1.59% 0
29/09/26 €12.60 -2.33% 0
28/09/26 €12.90 -2.27% 0
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
14
Last Close Price
2,245.00JPY
Average target price
2,529.29JPY
Spread / Average Target
+12.66%

Quarterly revenue - Rate of surprise